Bull Run

Advanced stock screening and portfolio analysis for Indian equity markets.

Navigation

Tools & Features

  • Premium Features
© 2025 Bull Run. All rights reserved.
info@bullrun.co.in

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities. Bull Run is not a SEBI-registered Research Analyst/Investment Adviser.

HomeStocksIT Enabled ServicesKashyap Tele Medicines Ltd

Kashyap Tele Medicines Ltd Stock Price Today (NSE: KASHYAP)

Kashyap Tele Medicines Ltd

KASHYAPIT Enabled Services
₹5.60+₹0.00 (+0.00%)↑
As on 17 Feb 2026, 10:14 am ISTMarket Closed

Fundamental Score

...

Kashyap Tele Medicines Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis

Kashyap Tele Medicines Ltd share price today is ₹5.60, up +0.00% on NSE/BSE as of 17 February 2026. Kashyap Tele Medicines Ltd (KASHYAP) is a Small-cap company in the IT Enabled Services sector with a market capitalisation of ₹45.19 (Cr). The 52-week high for KASHYAP share price is ₹N/A and the 52-week low is ₹N/A. 0

Kashyap Tele Medicines Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
₹0.00
Low
₹0.00
Volume
0
Change
+0.00%

Returns & Performance

Poor

ROE

0.00%
Poor

ROCE

0.00%
Poor

OPM (5Y)

-13.40%

Div Yield

0.00%

Kashyap Tele Medicines Ltd Valuation Check

P/E Ratio

N/A
Poor

Industry P/E

33.81x
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Market Cap

45.19 (Cr)

Growth Engine

Profit Growth (Q)

N/A
Poor

Sales Growth (Q)

-100.00%
Poor

Sales Growth (5Y)

-1.02%

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Balance Sheet Health

Excellent

Debt to Equity

0.00x

Int. Coverage

N/A

Free Cash Flow (5Y)

-0.10 (Cr)

Shareholding

Excellent

Promoter

61.93%
Poor

FII

0.00%
Poor

DII

0.06%
Excellent

Pledged

0.00%

Institutional Deep-Dive

Bull Run Research Hub

Kashyap Tele Medicines Share Price Analysis: A ROCE Efficiency Perspective

In the dynamic IT-Enabled Services (ITES) sector, characterized by rapid technological advancements and evolving customer demands, Return on Capital Employed (ROCE) serves as a crucial indicator of a company’s efficiency in utilizing capital to generate profits. This analysis focuses on Kashyap Tele Medicines share price (₹6.19) through the lens of ROCE, a key metric for assessing financial performance. This assessment is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.

Currently, Kashyap Tele Medicines Ltd. reports a ROCE of 0.0%. This figure raises concerns about the company's profitability relative to the capital invested in the business. A low ROCE suggests the company may not be effectively deploying its assets to generate returns, potentially indicating inefficiencies in operations, high operating costs, or low revenue generation. Comparing this with sector peers highlights the discrepancy. FCS Software Solutions Ltd, for instance, might exhibit different management approaches which impact the perceived quality of the leadership and their ability to deploy capital effectively. Ultimately, management effectiveness strongly influences the success of an ITES company.

The absence of a Price-to-Earnings (PE) ratio further complicates the analysis, potentially indicating the company isn’t profitable or has negative earnings. In contrast, peers like Euphoria Infotech India Ltd and Protean eGov Technologies Ltd may have positive PE ratios, providing a benchmark for comparison within the ITES landscape. A robust ROCE generally contributes to a stronger competitive moat, reflecting the company's ability to sustain profitability and fend off competition. A 0.0% ROCE, however, suggests a weak or non-existent moat. Competitors could potentially offer similar services at lower prices or with greater efficiency, eroding Kashyap Tele Medicines Ltd's market position.

The ITES sector rewards companies that can effectively leverage technology and human capital to deliver value-added services. Continuous monitoring of financial ratios, particularly ROCE, is essential for understanding the long-term sustainability and growth potential of companies operating within this sector. It will be critical to observe how Kashyap Tele Medicines Ltd. addresses its ROCE challenges and whether strategic changes are implemented to improve capital efficiency and overall financial health.

SM
Analysis by Sweta Mishra
SEBI Registered Research Analyst

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Kashyap Tele Medicines Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of KASHYAP across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Balanced Promoter Holding (61.93%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (0.00%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (0.00%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-13.40%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Revenue Contraction (-100.00%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-1.02% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Negative Free Cash Flow (₹-0.10 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 0.06%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Kashyap Tele Medicines Ltd Financial Statements

Comprehensive financial data for Kashyap Tele Medicines Ltd including income statement, balance sheet and cash flow

About KASHYAP (Kashyap Tele Medicines Ltd)

Kashyap Tele Medicines Ltd (KASHYAP) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the IT Enabled Services sector with a current market capitalisation of ₹45.19 (Cr).0 The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking KASHYAP share price can monitor key metrics including P/E ratio, promoter holding of 61.93%, and quarterly earnings growth.

Company Details

Symbol:KASHYAP
Industry:IT Enabled Services
Sector:IT Enabled Services
Website:https://kashyaptele-medicines.com

Key Leadership

Mr. Kalpesh Bipin Sheth
MD & Executive Director
Mr. Anirudh Shah
Chief Financial Officer
Ms. Varsha Sawant
Company Secretary & Compliance Officer

Latest News

Kashyap Tele-Medicines - 14 Penny stocks surged up to 440% in CY25; 6 emerge as multibaggers. Did you own any? - The Economic Times
The Economic Times• 12/28/2025
Stocks to Watch Today: HCLTech, RBL Bank, Atlantaa, Zydus Life, Ion Exchange, Solex Energy, BL Kashyap,... - Moneycontrol
Moneycontrol• 12/16/2025
B L Kashyap & Sons secures ₹1,067 crore worth of orders in 2 days, equal to 65% of its market cap - livemint.com
livemint.com• 7/22/2025

KASHYAP Share Price: Frequently Asked Questions

What is the current share price of Kashyap Tele Medicines Ltd (KASHYAP)?

As of 17 Feb 2026, 10:14 am IST, Kashyap Tele Medicines Ltd share price is ₹5.60. The KASHYAP stock has a market capitalisation of ₹45.19 (Cr) on NSE/BSE.

Is KASHYAP share price Overvalued or Undervalued?

KASHYAP share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 33.81x. Based on this relative valuation, the Kashyap Tele Medicines Ltd stock appears to be Fairly Valued against its sector peers.

What is the 52-week high and low of KASHYAP share price?

The 52-week high of KASHYAP share price is ₹N/A and the 52-week low is ₹N/A.

What factors affect the Kashyap Tele Medicines Ltd share price?

Key factors influencing KASHYAP share price include quarterly earnings growth (Sales Growth: -100.00%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Kashyap Tele Medicines Ltd a good stock for long-term investment?

Kashyap Tele Medicines Ltd shows a 5-year Profit Growth of N/A% and an ROE of 0.00%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in KASHYAP shares.

How does Kashyap Tele Medicines Ltd compare with its industry peers?

Kashyap Tele Medicines Ltd competes with major peers in the IT Enabled Services. Investors should compare KASHYAP share price P/E of 0.00x and ROE of 0.00% against the industry averages to determine competitive standing.

What is the P/E ratio of KASHYAP and what does it mean?

KASHYAP share price has a P/E ratio of N/Ax compared to the industry average of 33.81x. Investors pay ₹N/A for every ₹1 of annual earnings.

How is KASHYAP performing according to Bull Run's analysis?

KASHYAP has a Bull Run fundamental score of 8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.

What sector and industry does KASHYAP belong to?

KASHYAP operates in the IT Enabled Services industry. This classification helps understand the competitive landscape and sector-specific trends affecting Kashyap Tele Medicines Ltd share price.

What is Return on Equity (ROE) and why is it important for KASHYAP?

KASHYAP has an ROE of 0.00%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Kashyap Tele Medicines Ltd generates profits from shareholders capital.

How is KASHYAP debt-to-equity ratio and what does it indicate?

KASHYAP has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.

What is KASHYAP dividend yield and is it a good dividend stock?

KASHYAP offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Kashyap Tele Medicines Ltd shares.

How has KASHYAP share price grown over the past 5 years?

KASHYAP has achieved 5-year growth rates of: Sales Growth -1.02%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in KASHYAP and why does it matter?

Promoters hold 61.93% of KASHYAP shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Kashyap Tele Medicines Ltd.

What is KASHYAP market capitalisation category?

KASHYAP has a market capitalisation of ₹45 crores, placing it in the Small-cap category.

How volatile is KASHYAP stock?

KASHYAP has a beta of N/A. A beta > 1 suggests the Kashyap Tele Medicines Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is KASHYAP operating profit margin trend?

KASHYAP has a 5-year average Operating Profit Margin (OPM) of -13.40%, indicating the company's operational efficiency.

How is KASHYAP quarterly performance?

Recent quarterly performance shows Kashyap Tele Medicines Ltd YoY Sales Growth of -100.00% and YoY Profit Growth of N/A%.

What is the institutional holding pattern in KASHYAP?

KASHYAP has FII holding of 0.00% and DII holding of 0.06%. Significant institutional holding often suggests professional confidence in the Kashyap Tele Medicines Ltd stock.

HomeScreenerBattleWatchlist